Jul 2 |
Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
|
May 30 |
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
|
May 24 |
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
|
May 23 |
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
|
May 10 |
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
|
May 10 |
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
|
May 9 |
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
|
May 9 |
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
|
May 9 |
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
May 9 |
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
|